Abstract
A quantitative structure-activity relationship (QSAR) study has been made on two different series of anticancer tyrosine kinase inhibitors, namely a series of 4-alkynyl and 4-alkenyl-quinazolines and a series of N-4,6-pyrimidine-Nalkyl- N'-phenyl ureas. For the first series, QSAR results indicate that the activity is controlled by the hydrophobicity of the molecules and molecular connectivity index of the substituent, whereas for the second series of compounds the activity is found to be controlled by the molecular connectivity index of the substituent and some indicator variables.
Keywords: Quantitative structure-activity relationship, Tyrosine kinase inhibitors, Lck inhibitors, Endothelial growth factor receptor (EGFR), 4-alkynylquinazolines, 4-alkenylquinazolines, N-4, 6-pyrimidine-N-alkyl-N’-phenyl ureas.
Medicinal Chemistry
Title:A QSAR Study on Some Series of Anticancer Tyrosine Kinase Inhibitors
Volume: 9 Issue: 2
Author(s): Zaihra Anwer and Satya P. Gupta
Affiliation:
Keywords: Quantitative structure-activity relationship, Tyrosine kinase inhibitors, Lck inhibitors, Endothelial growth factor receptor (EGFR), 4-alkynylquinazolines, 4-alkenylquinazolines, N-4, 6-pyrimidine-N-alkyl-N’-phenyl ureas.
Abstract: A quantitative structure-activity relationship (QSAR) study has been made on two different series of anticancer tyrosine kinase inhibitors, namely a series of 4-alkynyl and 4-alkenyl-quinazolines and a series of N-4,6-pyrimidine-Nalkyl- N'-phenyl ureas. For the first series, QSAR results indicate that the activity is controlled by the hydrophobicity of the molecules and molecular connectivity index of the substituent, whereas for the second series of compounds the activity is found to be controlled by the molecular connectivity index of the substituent and some indicator variables.
Export Options
About this article
Cite this article as:
Anwer Zaihra and P. Gupta Satya, A QSAR Study on Some Series of Anticancer Tyrosine Kinase Inhibitors, Medicinal Chemistry 2013; 9 (2) . https://dx.doi.org/10.2174/1573406411309020005
DOI https://dx.doi.org/10.2174/1573406411309020005 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine Old Drugs-Current Perspectives
Current Pharmacogenomics Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Multiple Functions of Rad9 for Preserving Genomic Integrity
Current Genomics Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Topomer CoMFA 3D-QSAR and Docking Studies of Pyrimidine Inhibitors of Pneumocystis Carinii Dihydrofolate Reductase
Letters in Drug Design & Discovery Synthesis and in vitro Cytotoxicity Studies of Certain Novel Heterocycles Derived from Bis 1, 2, 4-Triazoles and their DNA Damage Studies
Medicinal Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Active Targeting Strategies for Anticancer Drug Nanocarriers
Current Drug Delivery Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Monitoring Therapy with Gene Expression Profiling Reveals Physiological Differences in Drug Action
Current Pharmaceutical Design